Weekly shot may replace daily growth hormone for turner syndrome kids

NCT ID NCT05690386

Ongoing Disease control Sponsor: Ascendis Pharma Endocrinology Division A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new long-acting growth hormone (lonapegsomatropin) given once a week, compared to the standard daily growth hormone shot, in 48 prepubertal children with Turner syndrome who have not had growth hormone before. The goal is to see if the weekly shot is safe and helps children grow as well as the daily shot. Participants will be randomly assigned to one of three doses of the weekly drug or the daily drug, and their growth will be tracked for up to 2 years, with an optional extension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Turner syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TURNER SYNDROME

Contacts and locations

Locations

Ascendis Pharma Investigational Site

Palo Alto, California, 94304, United States
Ascendis Pharma Investigational Site

San Diego, California, 92123, United States
Ascendis Pharma Investigational Site

Aurora, Colorado, 80045, United States
Ascendis Pharma Investigational Site

Orlando, Florida, 32827, United States
Ascendis Pharma Investigational Site

St. Petersburg, Florida, 33701-4804, United States
Ascendis Pharma Investigational Site

Atlanta, Georgia, 30322, United States
Ascendis Pharma Investigational Site

Idaho Falls, Idaho, 83404, United States
Ascendis Pharma Investigational Site

Chicago, Illinois, 60611, United States
Ascendis Pharma Investigational Site

Boston, Massachusetts, 02114, United States
Ascendis Pharma Investigational Site

Saint Paul, Minnesota, 55102, United States
Ascendis Pharma Investigational Site

Las Vegas, Nevada, 89113, United States
Ascendis Pharma Investigational Site

Lake Success, New York, 11042, United States
Ascendis Pharma Investigational Site

Chapel Hill, North Carolina, 27599, United States
Ascendis Pharma Investigational Site

Cincinnati, Ohio, 45229, United States
Ascendis Pharma Investigational Site

Oklahoma City, Oklahoma, 73104, United States
Ascendis Pharma Investigational Site

Portland, Oregon, 97239, United States
Ascendis Pharma Investigational Site

El Paso, Texas, 79902, United States
Ascendis Pharma Investigational Site

Fort Worth, Texas, 76104, United States
Ascendis Pharma Investigational Site

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.